See more : American Financial Group, Inc. (AFG) Income Statement Analysis – Financial Results
Complete financial analysis of Teligent, Inc. (TLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Teligent, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lakeshore Acquisition II Corp. (LBBB) Income Statement Analysis – Financial Results
- Sumitomo Seika Chemicals Company, Limited. (4008.T) Income Statement Analysis – Financial Results
- Spindletop Health Acquisition Corp. (SHCA) Income Statement Analysis – Financial Results
- M8 Sustainable Limited (M8S.AX) Income Statement Analysis – Financial Results
- Hextar Technologies Solutions Berhad (5136.KL) Income Statement Analysis – Financial Results
Teligent, Inc. (TLGT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.teligent.com
About Teligent, Inc.
Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.
| Metric | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.31M | 65.90M | 67.25M | 66.88M | 44.25M | 33.74M | 18.22M | 8.56M | 7.81M | 6.09M | 3.78M | 4.07M | 4.58M | 2.62M | 2.87M | 3.56M | 3.56M | 4.36M | 15.90M | 19.25M | 34.59M | 33.20M | 34.20M | 35.10M | 31.20M | 28.90M | 28.00M | 24.40M | 22.00M | 20.10M | 18.30M | 16.00M | 15.70M | 18.40M | 17.80M |
| Cost of Revenue | 0.00 | 42.37M | 39.88M | 32.19M | 22.94M | 16.95M | 12.08M | 5.79M | 5.55M | 4.99M | 3.53M | 2.85M | 2.48M | 1.39M | 1.92M | 1.25M | 1.35M | 1.38M | 8.77M | 9.19M | 16.46M | 16.00M | 16.80M | 15.10M | 14.60M | 13.10M | 12.20M | 10.20M | 9.70M | 8.70M | 8.00M | 7.00M | 6.80M | 7.90M | 8.50M |
| Gross Profit | 45.31M | 23.52M | 27.37M | 34.69M | 21.32M | 16.79M | 6.15M | 2.78M | 2.26M | 1.11M | 251.00K | 1.22M | 2.11M | 1.23M | 947.00K | 2.31M | 2.21M | 2.99M | 7.13M | 10.06M | 18.14M | 17.20M | 17.40M | 20.00M | 16.60M | 15.80M | 15.80M | 14.20M | 12.30M | 11.40M | 10.30M | 9.00M | 8.90M | 10.50M | 9.30M |
| Gross Profit Ratio | 100.00% | 35.70% | 40.70% | 51.86% | 48.17% | 49.77% | 33.72% | 32.42% | 28.95% | 18.13% | 6.64% | 29.93% | 45.95% | 47.02% | 33.03% | 64.78% | 62.19% | 68.42% | 44.85% | 52.24% | 52.43% | 51.81% | 50.88% | 56.98% | 53.21% | 54.67% | 56.43% | 58.20% | 55.91% | 56.72% | 56.28% | 56.25% | 56.69% | 57.07% | 52.25% |
| Research & Development | 548.00K | 10.76M | 19.27M | 17.14M | 13.17M | 6.91M | 2.74M | 2.83M | 2.15M | 1.51M | 740.00K | 502.00K | 481.00K | 1.07M | 949.00K | 1.73M | 762.00K | 549.00K | 536.00K | 853.00K | 1.42M | 1.40M | 1.70M | 2.00M | 1.30M | 800.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 7.99M | 14.06M | 15.70M | 15.00M | 15.00M | 11.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 20.79M | 19.90M | 15.01M | 11.34M | 5.98M | 3.48M | 3.08M | 3.08M | 3.23M | 3.60M | 2.78M | 2.43M | 2.11M | 1.68M | 1.80M | 2.42M | 2.36M | 1.42M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 11.50M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Operating Expenses | 548.00K | 31.54M | 39.17M | 32.15M | 24.51M | 12.89M | 6.23M | 5.91M | 5.23M | 4.74M | 4.34M | 3.28M | 2.91M | 3.17M | 2.63M | 3.53M | 3.18M | 2.91M | 7.29M | 10.22M | 16.63M | 18.10M | 17.70M | 18.00M | 14.00M | 12.30M | 12.50M | 13.80M | 11.70M | 10.40M | 9.60M | 8.10M | 7.50M | 7.90M | 8.40M |
| Cost & Expenses | 548.00K | 73.92M | 79.05M | 64.34M | 47.44M | 29.83M | 18.31M | 11.70M | 10.78M | 9.73M | 7.87M | 6.13M | 5.39M | 4.56M | 4.55M | 4.78M | 4.53M | 4.29M | 16.06M | 19.41M | 33.09M | 34.10M | 34.50M | 33.10M | 28.60M | 25.40M | 24.70M | 24.00M | 21.40M | 19.10M | 17.60M | 15.10M | 14.30M | 15.80M | 16.90M |
| Interest Income | 0.00 | -21.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -962.00K | 17.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.61M | 0.00 | 0.00 | 0.00 | 0.00 | 13.00K | 281.00K | 13.00K | 938.00K | 0.00 | 48.00K | 129.00K | 4.00K | 0.00 | 0.00 | 283.00K | 2.13M | 2.75M | 0.00 | 3.40M | 0.00 | 2.00M | 1.30M | 1.00M | 600.00K | 700.00K | 600.00K | 800.00K | 700.00K | 500.00K | 0.00 | 800.00K | 1.00M |
| Depreciation & Amortization | 6.55M | 6.70M | 4.64M | 3.78M | 1.17M | 515.00K | 475.00K | 457.00K | 419.00K | 376.00K | 348.00K | 349.00K | 336.00K | 371.00K | 300.00K | 271.00K | 269.00K | 581.00K | 1.03M | 1.37M | 1.15M | 1.00M | 1.00M | 1.00M | 800.00K | 800.00K | 1.00M | 1.10M | 900.00K | 700.00K | 700.00K | 600.00K | 600.00K | 700.00K | 900.00K |
| EBITDA | 48.60M | -18.34M | -9.02M | -7.92M | 7.88M | 5.94M | 194.00K | -3.64M | -2.53M | -3.25M | -3.74M | -1.70M | -401.00K | -1.63M | -1.27M | -911.00K | -261.00K | 9.97M | 1.15M | -10.22M | -1.04M | 100.00K | -1.10M | 3.00M | 200.00K | 2.70M | -1.60M | 1.80M | 1.60M | 1.70M | 1.40M | 1.40M | 2.10M | 2.90M | 1.10M |
| EBITDA Ratio | 107.27% | -27.83% | -13.42% | -11.84% | 17.80% | 17.60% | 1.06% | -42.52% | -32.45% | -53.35% | -99.05% | -41.75% | -8.75% | -62.02% | -44.40% | -25.60% | -7.34% | 228.55% | 7.22% | -53.10% | -2.99% | 0.30% | -3.22% | 8.55% | 0.64% | 9.34% | -5.71% | 7.38% | 7.27% | 8.46% | 7.65% | 8.75% | 13.38% | 15.76% | 6.18% |
| Operating Income | 44.76M | -8.02M | -11.80M | 2.54M | -3.19M | 3.91M | -82.00K | -3.14M | -2.97M | -3.63M | -4.09M | -2.06M | -806.00K | -1.94M | -1.68M | -1.22M | -972.00K | 79.00K | -161.00K | -157.00K | 1.51M | -900.00K | -300.00K | 2.00M | 2.60M | 3.50M | 3.30M | 400.00K | 600.00K | 1.00M | 700.00K | 900.00K | 1.40M | 2.60M | 900.00K |
| Operating Income Ratio | 98.79% | -12.17% | -17.54% | 3.80% | -7.21% | 11.58% | -0.45% | -36.62% | -38.03% | -59.58% | -108.28% | -50.65% | -17.59% | -73.97% | -58.60% | -34.29% | -27.33% | 1.81% | -1.01% | -0.82% | 4.35% | -2.71% | -0.88% | 5.70% | 8.33% | 12.11% | 11.79% | 1.64% | 2.73% | 4.98% | 3.83% | 5.63% | 8.92% | 14.13% | 5.06% |
| Total Other Income/Expenses | 548.00K | -17.01M | -3.48M | -14.24M | 9.90M | 1.52M | -199.00K | -975.00K | -264.00K | -9.00K | -937.00K | 13.00K | 16.00K | -129.00K | 103.00K | 38.00K | 7.00K | -225.00K | -2.13M | -2.75M | -4.08M | -3.40M | -1.80M | 0.00 | -500.00K | -900.00K | -600.00K | 200.00K | 0.00 | -1.10M | 0.00 | 0.00 | 100.00K | -1.00M | -1.00M |
| Income Before Tax | 45.31M | -25.03M | -15.28M | -11.70M | 6.70M | 5.42M | -281.00K | -4.11M | -3.23M | -3.64M | -5.03M | -2.05M | -790.00K | -2.07M | -1.58M | -1.18M | -965.00K | -146.00K | -2.29M | -2.91M | -2.57M | -4.30M | -2.10M | 0.00 | 2.10M | 2.60M | 2.70M | 600.00K | 0.00 | -100.00K | 0.00 | 0.00 | 1.50M | 1.60M | -100.00K |
| Income Before Tax Ratio | 100.00% | -37.99% | -22.71% | -17.49% | 15.15% | 16.08% | -1.54% | -48.01% | -41.42% | -59.73% | -133.09% | -50.33% | -17.25% | -78.89% | -55.01% | -33.22% | -27.13% | -3.35% | -14.43% | -15.12% | -7.43% | -12.95% | -6.14% | 0.00% | 6.73% | 9.00% | 9.64% | 2.46% | 0.00% | -0.50% | 0.00% | 0.00% | 9.55% | 8.70% | -0.56% |
| Income Tax Expense | 45.31M | 91.00K | -85.00K | 287.00K | 35.00K | 173.00K | -197.00K | -184.00K | -226.00K | -217.00K | -108.00K | -196.00K | -453.00K | -458.00K | -279.00K | -290.00K | -208.00K | 330.00K | -271.00K | 5.86M | -601.00K | -1.30M | -600.00K | -100.00K | 600.00K | 600.00K | 900.00K | -100.00K | 600.00K | -200.00K | 0.00 | 500.00K | 700.00K | 1.00M | 500.00K |
| Net Income | 0.00 | -25.12M | -15.19M | -11.99M | 6.67M | 5.25M | -84.00K | -3.93M | -3.01M | -3.42M | -4.92M | -1.85M | -332.00K | -1.67M | -1.30M | -892.00K | -322.00K | 8.78M | -1.74M | -20.21M | -1.58M | -3.00M | -1.50M | 100.00K | -2.50M | 300.00K | -4.10M | 100.00K | 100.00K | 100.00K | 0.00 | 300.00K | 800.00K | 400.00K | -1.30M |
| Net Income Ratio | 0.00% | -38.13% | -22.59% | -17.92% | 15.07% | 15.56% | -0.46% | -45.86% | -38.52% | -56.17% | -130.23% | -45.51% | -7.25% | -63.63% | -45.27% | -25.07% | -9.05% | 201.19% | -10.94% | -104.99% | -4.58% | -9.04% | -4.39% | 0.28% | -8.01% | 1.04% | -14.64% | 0.41% | 0.45% | 0.50% | 0.00% | 1.88% | 5.10% | 2.17% | -7.30% |
| EPS | 0.00 | -4.67 | -2.85 | -2.26 | 1.26 | 1.05 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.77 | -0.28 | 7.68 | -1.59 | -19.81 | -1.65 | -3.17 | -1.59 | 0.10 | -2.57 | 0.30 | -4.90 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| EPS Diluted | 0.00 | -4.67 | -2.85 | -2.26 | 0.99 | 0.82 | -0.02 | -0.99 | -0.76 | -2.30 | -3.31 | -1.24 | -0.23 | -1.30 | -1.08 | -0.74 | -0.28 | 7.68 | -1.59 | -19.81 | -1.58 | -3.17 | -1.59 | 0.10 | -2.50 | 0.30 | -4.60 | 0.10 | 0.10 | 0.20 | 0.00 | 0.30 | 1.00 | 0.60 | -1.80 |
| Weighted Avg Shares Out | 77.14M | 5.38M | 5.33M | 5.31M | 5.29M | 4.98M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.15M | 1.14M | 1.14M | 1.10M | 1.02M | 960.48K | 947.04K | 945.79K | 1.00M | 972.52K | 1.00M | 836.74K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
| Weighted Avg Shares Out (Dil) | 77.14M | 5.38M | 5.33M | 5.31M | 6.71M | 6.42M | 3.98M | 3.98M | 3.94M | 1.49M | 1.49M | 1.49M | 1.43M | 1.28M | 1.20M | 1.20M | 1.15M | 1.14M | 1.10M | 1.02M | 1.00M | 947.04K | 945.79K | 1.00M | 1.00M | 1.00M | 891.30K | 1.00M | 1.00M | 500.00K | 666.67K | 1.00M | 800.00K | 666.67K | 722.22K |
Robbins Arroyo LLP: Teligent, Inc. (TLGT) Misled Shareholders According to a Recently Filed Lawsuit
SAN DIEGO & BUENA, N.J.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Teligent, Inc. (NASDAQ: TLGT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between May 2, 2017...
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Teligent, Inc. (TLGT)
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Teligent, Inc. (“Teligent” or the “Company”) (NASDAQ: TLGT) and one of its executives...
Robbins Arroyo LLP Is Investigating the Officers and Directors of Teligent, Inc. (TLGT) on Behalf of Shareholders
SAN DIEGO & BUENA, N.J.--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Teligent, Inc. (NASDAQGS: TLGT) breached their fiduciary duties to shareholders. Teligent, a specialty generic pharmaceutical company, develops, formulates, manufactures, and...
Source: https://incomestatements.info
Category: Stock Reports